ICON Further Enhances Clinical Trial Feasibility, Protocol Optimisation and Patient Recruitment Capabilities with TriNetX
October 27 2016 - 5:00AM
Business Wire
ICON applies real-world health research
network to improve clinical development
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has further improved its feasibility, protocol optimisation and
patient recruitment capabilities through the use of TriNetX.
TriNetX is a research network and technology platform connecting
ICON to the Electronic Medical Record (EMR) systems of a rapidly
expanding network of healthcare organisations representing over 57
million patient lives globally. Through TriNetX, ICON is conducting
real-time feasibility reviews by analysing patient populations with
search criteria across multiple data points and assessing the
inclusion and exclusion criteria that have the most impact on
patient recruitment. Each data point in the TriNetX system can be
traced to healthcare organisations who have the ability to identify
individual patients, enabling ICON to develop virtual patient
cohorts that can be found in real-world clinical trial settings.
ICON incorporates the use of EMRs in all new client studies and has
already conducted over 300 feasibility reviews utilizing TriNetX
across multiple therapeutic areas.
The use of TriNetX is another example of ICON’s leadership in
applying targeted technology to help customers reduce the time and
cost of their development programmes through more accurate patient
identification and faster patient recruitment. It follows ICON’s
application of cognitive computing capabilities to clinical trial
feasibility and patient recruitment. ICON’s ability to recruit
patients is also strengthened through a wholly owned site network –
PMG Research – with access to over 2 million active patient lives,
as well as site partnerships with clinical research sites at
healthcare systems and community physician practices all over the
world.
Commenting on today’s announcement, ICON’s Chief Operating
Officer, Dr. Steve Cutler, said: “Access to EMR systems offers new
opportunities for more efficient selection of sites and patient
recruitment. TriNetX offers robust query and analytics tools that
enable real-time analyses of patient populations which are helping
our customers design better protocols, select the right sites and
recruit patients faster. ICON’s use of TriNetX is a further example
of our commitment to deploy industry-leading technologies that help
customers overcome complex clinical development challenges.”
“ICON is leveraging the health research network to help
pharmaceutical, biotechnology and medical device clients bring new
therapies to market faster. TriNetX is pleased to support a world
leader improving the efficiency of drug development,” said Gadi
Lachman, CEO, TriNetX, Inc.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 77 locations in 38 countries and has approximately
12,600 employees.
Further information is available at www.iconplc.com.
About TriNetX, Inc.
TriNetX is the worldwide health research network of healthcare
organizations, biopharmaceutical companies and contract research
organizations used to enhance clinical trial design and accelerate
patient recruitment. TriNetX enables researchers to find the right
patients at the right sites for clinical trials. For more
information, visit http://www.trinetx.com.
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161027005003/en/
For ICONCamille FrederixWeber Shandwick+44 (0) 207 067
0272cfrederix@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Sep 2023 to Sep 2024